Given the convergence of in vitro and in vivo evidence substantiating the involvement of p-Y158 PARP1 in PARPi resistance, we undertook the development of a monoclonal antibody against p-Y158 PARP1 for use in tumor immunohistochemistry (IHC) staining. The gene discussed is PARP1; the disease is neoplasm.